{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:59:25Z","timestamp":1783537165548,"version":"3.55.0"},"reference-count":100,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Nipah virus (NiV) is a highly pathogenic zoonotic pathogen. Since its discovery in 1998, recurrent epidemics have occurred in South and Southeast Asia, with a case fatality rate ranging from 40% to 100%. The outbreak in West Bengal, India in early 2026 has once again highlighted its severe threat to public health. To date, no licensed human vaccines or specific therapeutics against NiV are available worldwide. This review systematically summarizes the breakthroughs in antigen design for NiV vaccines, with a focus on conformational stabilization of prefusion F (pre-F) protein, chimeric G\/F antigens, and multivalent nanoparticle strategies. In addition, we comparatively analyze the clinical progress of mainstream vaccine platforms, including viral vectors, mRNA and subunit vaccines. Given the sporadic nature and high mortality of NiV infection, the conventional licensing pathway relying on large-scale phase III clinical trials faces substantial practical obstacles. Accordingly, this article discusses adaptive adjustments in regulatory science. We propose several strategies to accelerate the clinical translation and emergency stockpiling of NiV vaccine candidates, including establishing unified correlates of protection thresholds, coordinating multinational regulatory resources, and optimizing the implementation of Animal Rule.<\/jats:p>","DOI":"10.3390\/vaccines14070584","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:50:37Z","timestamp":1782867037000},"page":"584","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges, Advances, and Future Directions in Nipah Virus Vaccine Development"],"prefix":"10.3390","volume":"14","author":[{"given":"Hongshan","family":"Xu","sequence":"first","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shang","sequence":"additional","affiliation":[{"name":"Changchun Biological Products Research Institute Co., Ltd., Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Changchun Biological Products Research Institute Co., Ltd., Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunying","family":"Mao","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3201\/eid2204.151747","article-title":"Nipah Virus Transmission from Bats to Humans Associated with Drinking Traditional Liquor Made from Date Palm Sap, Bangladesh, 2011\u20132014","volume":"22","author":"Islam","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3201\/eid1508.081237","article-title":"Recurrent Zoonotic Transmission of Nipah Virus into Humans, Bangladesh, 2001\u20132007","volume":"15","author":"Luby","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1286-4579(01)01382-X","article-title":"Laboratory diagnosis of Nipah and Hendra virus infections","volume":"3","author":"Daniels","year":"2001","journal-title":"Microbes Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s11684-024-1078-2","article-title":"Nipah virus: Epidemiology, pathogenesis, treatment, and prevention","volume":"18","author":"Wang","year":"2024","journal-title":"Front. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1016\/j.vaccine.2015.12.075","article-title":"Status of vaccine research and development of vaccines for Nipah virus","volume":"34","author":"Satterfield","year":"2016","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/647951","article-title":"Transmission of human infection with Nipah virus","volume":"49","author":"Luby","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Faus-Cotino, J., Reina, G., and Pueyo, J. (2024). Nipah virus: A multidimensional update. Viruses, 16.","DOI":"10.3390\/v16020179"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1556\/1886.2025.00017","article-title":"Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development","volume":"15","author":"Salleh","year":"2025","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jcv.2008.08.007","article-title":"The emergence of Nipah virus, a highly pathogenic paramyxovirus","volume":"43","author":"Lo","year":"2008","journal-title":"J. Clin. Virol."},{"key":"ref_10","first-page":"3128","article-title":"Nipah: Silently rising infection","volume":"9","author":"Chanchal","year":"2018","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01875-17","DOI":"10.1128\/JCM.01875-17","article-title":"Nipah virus infection","volume":"56","author":"Ang","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_12","unstructured":"World Health Organization (2026, March 29). Nipah Virus Infection\u2014Global. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/_sage-2026\/who-rapid-risk-assessment---nipah-virus---global-v.1.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100434","DOI":"10.1016\/j.ijregi.2024.100434","article-title":"Twenty-five years of Nipah outbreaks in Southeast Asia: A persistent threat to global health","volume":"13","author":"Khan","year":"2024","journal-title":"IJID Reg."},{"key":"ref_14","unstructured":"World Health Organization (2026, April 04). Nipah Virus Infection. Available online: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/71e6f411-f727-48db-a26d-352ed00881fd\/content."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0012823","DOI":"10.1128\/cmr.00128-23","article-title":"Henipaviruses: Epidemiology, ecology, disease, and the development of vaccines and therapeutics","volume":"38","author":"Spengler","year":"2025","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108010","DOI":"10.1016\/j.ijid.2025.108010","article-title":"Epidemiology, clinical characteristics, and genetic diversity of Nipah virus strains from Bangladesh: 2016\u20132023","volume":"159","author":"Satter","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_17","unstructured":"World Health Organization (2026, April 08). Disease Outbreak News (DONs). Available online: https:\/\/www.who.int\/southeastasia\/outbreaks-and-emergencies\/nipah-virus."},{"key":"ref_18","unstructured":"Coalition for Epidemic Preparedness Innovations (2026, April 08). University of Oxford Launches World\u2019s first Phase II Nipah Virus Vaccine trial. Available online: https:\/\/cepi.net\/university-oxford-launches-worlds-first-phase-ii-nipah-virus-vaccine-trial."},{"key":"ref_19","unstructured":"University of Oxford (2026, April 08). World\u2019s First Phase II Nipah Virus Vaccine Trial Launch. Available online: https:\/\/www.ox.ac.uk\/news\/2025-12-15-worlds-first-phase-ii-nipah-virus-vaccine-trial-launch."},{"key":"ref_20","unstructured":"Public Health Vaccines LLC (2026, April 10). Public Health Vaccines Announces the Initiation of the First Clinical Trial Evaluating Its Nipah Virus Vaccine. Available online: https:\/\/phvaccines.com\/downloads\/Press-Release-Feb-09-2022.pdf."},{"key":"ref_21","unstructured":"Coalition for Epidemic Preparedness Innovations (2026, April 10). New Vaccine Set for Human Trials in Nipah Outbreak Hotspot. Available online: https:\/\/cepi.net\/new-vaccine-set-human-trials-nipah-outbreak-hotspot."},{"key":"ref_22","unstructured":"National Institutes of Health (2025, October 23). Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05398796."},{"key":"ref_23","unstructured":"(2026, April 10). Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine, mRNA-1215. Available online: https:\/\/news.modernatx.com\/news\/news-details\/2022\/Moderna-Announces-First-Participant-Dosed-in-a-Phase-1-Trial-of-its-Nipah-Virus-mRNA-Vaccine-mRNA-1215\/default.aspx."},{"key":"ref_24","unstructured":"National Institutes of Health (2022, November 17). Safety and Immunogenicity of a Nipah Virus Vaccine, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04199169."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41467-017-00863-3","article-title":"Monomeric ephrinB2 binding induces allosteric changes in Nipah virus G that precede its full activation","volume":"8","author":"Wong","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100291","DOI":"10.1016\/j.crpvbd.2025.100291","article-title":"Why the Jenner\/Pasteur paradigm is insufficient for controlling vector-borne diseases and the role of microbiota-mediated interactions","volume":"8","author":"Obregon","year":"2025","journal-title":"Curr. Res. Parasitol. Vector Borne Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14760584.2025.2476523","article-title":"Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response","volume":"24","author":"Kim","year":"2025","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_28","first-page":"120","article-title":"Research progress on animal models of Nipah virus infection","volume":"19","author":"Li","year":"2024","journal-title":"J. Microbes Infect."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lv, C., He, J., Zhang, Q., and Wang, T. (2025). Vaccines and animal models of Nipah virus: Current situation and future prospects. Vaccines, 13.","DOI":"10.3390\/vaccines13060608"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-virology-021920-113833","article-title":"Vaccines to emerging viruses: Nipah and Hendra","volume":"7","author":"Amaya","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S1744133112000321","article-title":"Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research","volume":"8","year":"2013","journal-title":"Health Econ. Policy Law."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Branda, F., Ceccarelli, G., Giovanetti, M., Albanese, M., Binetti, E., Ciccozzi, M., and Scarpa, F. (2025). Nipah virus: A zoonotic threat re-emerging in the wake of global public health challenges. Microorganisms, 13.","DOI":"10.3390\/microorganisms13010124"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S2666-5247(23)00361-0","article-title":"Nipah virus: A re-emerging public health concern","volume":"5","author":"Cui","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.22207\/JPAM.18.3.33","article-title":"A comprehensive review of Nipah virus: From epidemics to approaches of management","volume":"18","author":"Pandey","year":"2024","journal-title":"J. Pure Appl. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e0077025","DOI":"10.1128\/jvi.00770-25","article-title":"The intracellular virus-host interface of henipaviruses","volume":"99","author":"Tripp","year":"2025","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eadw4609","DOI":"10.1126\/sciadv.adw4609","article-title":"Nipah virus matrix protein uses cortical actin to stabilize the virus assembly sites and promote budding","volume":"11","author":"Wang","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"002206","DOI":"10.1099\/jgv.0.002206","article-title":"Coordinated interactions among Nipah virus N, P and M proteins drive formation of distinct inclusion bodies","volume":"106","author":"Yasukochi","year":"2025","journal-title":"J. Gen. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e19835","DOI":"10.7717\/peerj.19835","article-title":"Antigenic and mutational insights into the Nipah virus G glycoprotein: Implications for viral entry, host specificity, therapeutics, and vaccine development","volume":"13","author":"Ismadi","year":"2025","journal-title":"PeerJ"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2529505123","DOI":"10.1073\/pnas.2529505123","article-title":"Functional and antigenic constraints on the Nipah virus fusion protein","volume":"123","author":"Larsen","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1128\/JVI.02277-14","article-title":"Nipah virus attachment glycoprotein stalk C-terminal region links receptor binding to fusion triggering","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41541-025-01212-y","article-title":"Nipah virus vaccines evaluated in pigs as a \u2018One Health\u2019 approach to protect public health","volume":"10","author":"McLean","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/tmi.13979","article-title":"Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials","volume":"29","author":"Rodrigue","year":"2024","journal-title":"Trop. Med. Int. Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1038\/s41467-025-61764-4","article-title":"Cryo-EM structures of Nipah virus polymerases and high-throughput RdRp assay development enable anti-NiV drug discovery","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41467-025-57219-5","article-title":"Structural basis of Nipah virus RNA synthesis","volume":"16","author":"Sala","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eabn1440","DOI":"10.1126\/sciadv.abn1440","article-title":"Measles and Nipah virus assembly: Specific lipid binding drives matrix polymerization","volume":"8","author":"Norris","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1128\/JVI.78.11.5633-5641.2004","article-title":"Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively","volume":"78","author":"Shaw","year":"2004","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s42003-021-02797-5","article-title":"Nipah virus W protein harnesses nuclear 14-3-3 to inhibit NF-\u03baB-induced proinflammatory response","volume":"4","author":"Dumont","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2542-5196(24)00119-0","article-title":"Mapping the distribution of Nipah virus infections: A geospatial modelling analysis","volume":"8","author":"Sun","year":"2024","journal-title":"Lancet Planet. Health"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Cong, Y., Bearss, J., Mani, V., Lackemeyer, M., Pahar, B., Huzella, L.M., Kollins, E., Mazur, S., Dixit, S., and Lembirik, S. (2025). Large-particle aerosol exposure to the Bangladesh or Malaysia strain of Nipah virus results in markedly divergent disease presentation in African green monkeys. PLoS Pathog., 21.","DOI":"10.1371\/journal.ppat.1013835"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Swan, K., Salguero, F.J., Bird, A., Hunter, L., Kennard, C., Findlay-Wilson, S., Kennedy, E., Kempster, S., Almond, N., and Dowall, S. (2026). Histopathological and immunohistochemical characterization of lesions in the golden Syrian hamster model of Nipah virus infection (Bangladesh strain). Front. Vet. Sci., 12.","DOI":"10.3389\/fvets.2025.1708412"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e0231925","DOI":"10.1128\/spectrum.02319-25","article-title":"Mapping the geodispersal and evolutionary dynamics of regional Nipah virus strain in Bangladesh","volume":"14","author":"Rahman","year":"2026","journal-title":"Microbiol. Spectr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0317167100001785","article-title":"Nipah encephalitis outbreak in Malaysia, clinical features in patients from Seremban","volume":"29","author":"Chong","year":"2002","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_53","first-page":"439","article-title":"Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia","volume":"20017","author":"Yob","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S0950268815001314","article-title":"Evolving epidemiology of Nipah virus infection in Bangladesh: Evidence from outbreaks during 2010\u20132011","volume":"144","author":"Chakraborty","year":"2016","journal-title":"Epidemiol. Infect."},{"key":"ref_55","unstructured":"WHO (2025, September 18). Nipah Virus Infection\u2014Bangladesh. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON582."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/MS9.0000000000004319","article-title":"Nipah virus outbreak in Bangladesh: An enduring zoonotic threat","volume":"88","author":"Ali","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3201\/eid1902.120971","article-title":"Nipah Virus Infection Outbreak with Nosocomial and Corpse-to-Human Transmission, Bangladesh","volume":"19","author":"Sazzad","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"ref_58","first-page":"63","article-title":"Lessons from the Nipah virus outbreak in Malaysia","volume":"29","author":"Looi","year":"2007","journal-title":"Malays. J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Clayton, B.A., Middleton, D., Arkinstall, R., Frazer, L., Wang, L.-F., and Marsh, G.A. (2016). The Nature of Exposure Drives Transmission of Nipah Viruses from Malaysia and Bangladesh in Ferrets. PLoS Neglected Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004775"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"and Singh, S.K. (2026). The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness. PLoS Pathog., 22.","DOI":"10.1371\/journal.ppat.1014226"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101425","DOI":"10.1016\/j.nmni.2024.101425","article-title":"Nipah virus outbreak in the Indian subcontinent and means to counter it","volume":"60\u201361","author":"Kumar","year":"2024","journal-title":"New Microbes New Infect."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3201\/eid2608.190722","article-title":"Infections among Contacts of Patients with Nipah Virus, India","volume":"26","author":"Tan","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103878","DOI":"10.1016\/j.eclinm.2026.103878","article-title":"Post-acute sequelae after Nipah virus infection: A systematic review and meta-analysis","volume":"94","author":"Zhang","year":"2026","journal-title":"eClinicalMedicine"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.4103\/jpbs.jpbs_935_23","article-title":"NIPAH Virus Encephalitis: Unveiling the Epidemiology, Risk Factors, and Clinical Outcomes\u2014A Systematic Review and Meta-Analysis","volume":"16","author":"Suman","year":"2024","journal-title":"J. Pharm. Bioallied Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa1805376","article-title":"Transmission of Nipah Virus\u201414 Years of Investigations in Bangladesh","volume":"380","author":"Nikolay","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_67","unstructured":"IIslam, A., Choudhury, S.D., Islam, S., Khan, A.K.M.D., Chowdhury, N.N., Munro, S., Amin, E., Hosaain, M.E., Sultana, S., and Yinda, C.K. (2024, January 20\u201323). Understanding the Ecology and Epidemiology of Nipah Virus Spillover Events in Bangladesh. Proceedings of the 8th World One Health Congress, Cape Town, South Africa."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3201\/eid2309.161922","article-title":"Convergence of humans, bats, trees, and culture in Nipah virus transmission, Bangladesh","volume":"23","author":"Gurley","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hossain, H., Sakib, A.N., Sayeed, S.S.B., Rahman, M., Brishty, K.A., Pal, S.K., Rahman, T., Marma, C.S.S., Rafi, K.A., and Islam, S. (2025). Community knowledge and response to Nipah virus infection and its transmission, prevention and control measures: Insights from a cross-sectional survey in Bangladesh. PLoS Negl. Trop. Dis., 19.","DOI":"10.1371\/journal.pntd.0013855"},{"key":"ref_70","first-page":"77","article-title":"Epidemiological aspects of Nipah virus infection","volume":"4","author":"Goh","year":"1999","journal-title":"Neurol. J. Southeast. Asia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1386-6532(02)00268-8","article-title":"Nipah virus outbreak in Malaysia","volume":"26","author":"Chua","year":"2003","journal-title":"J. Clin. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.59096\/osir.v15i3.262364","article-title":"Secondary human-to-human transmission of Nipah virus in an ambulance, Northwestern Bangladesh, February 2019","volume":"15","author":"Alam","year":"2022","journal-title":"Outbreak Surveill. Investig. Response (OSIR) J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/infdis\/jiad467","article-title":"Potential for person-to-person transmission of henipaviruses: A systematic review of the literature","volume":"229","author":"Hegde","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"108683","DOI":"10.1016\/j.ijid.2026.108683","article-title":"Superspreading potential of Nipah virus disease despite self-limited human-to-human transmission in community","volume":"168","author":"Pan","year":"2026","journal-title":"Int. J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ricc\u00f2, M., Cascio, A., Costantino, C., Corrado, S., Zanella, I., Giuri, P.G., and Esposito, S. (2025). Risk of Nipah virus seroprevalence in healthcare workers: A systematic review with meta-analysis. Viruses, 17.","DOI":"10.3390\/v17010081"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Naidoo, T.M., Morgenstern, C., Doohan, P., Earl, R., Rawson, T., Sheppard, R.J., Hicks, J.T., Radhakrishnan, S., Johnson, R., and Hartner, A.-M. (2026). A Systematic Review of Nipah Virus Disease Epidemiological Parameters, Outbreaks and Mathematical Models. medRxiv.","DOI":"10.64898\/2026.03.19.26348815"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"29190","DOI":"10.1073\/pnas.2000429117","article-title":"Nipah virus dynamics in bats and implications for spillover to humans","volume":"117","author":"Epstein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s44298-026-00195-4","article-title":"Two geographies, one virus: What recurrent Nipah spillover in India reveals","volume":"4","author":"Patil","year":"2026","journal-title":"npj Viruses"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s10393-016-1166-0","article-title":"Investigating rare risk factors for Nipah virus in Bangladesh: 2001\u20132012","volume":"13","author":"Hegde","year":"2016","journal-title":"Ecohealth"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3201\/eid1307.061128","article-title":"Person-to-person transmission of Nipah virus in a Bangladeshi community","volume":"13","author":"Gurley","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1086\/315457","article-title":"Case-control study of risk factors for human infection with a new zoonotic paramyxovirus, Nipah virus, during a 1998\u20131999 outbreak of severe encephalitis in Malaysia","volume":"181","author":"Parashar","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM200004273421701","article-title":"Clinical features of Nipah virus encephalitis among pig farmers in Malaysia","volume":"342","author":"Goh","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"160","DOI":"10.20506\/rst.19.1.1202","article-title":"Nipah virus infection of pigs in peninsular Malaysia","volume":"19","author":"Gan","year":"2000","journal-title":"Rev. Sci. Tech."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"97","DOI":"10.9734\/jamb\/2026\/v26i51115","article-title":"Nipah Virus at the Human-Animal Interface: A Persistent Global Health Threat","volume":"26","author":"Fayaz","year":"2026","journal-title":"J. Adv. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3201\/eid1212.060732","article-title":"Foodborne transmission of Nipah virus, Bangladesh","volume":"12","author":"Luby","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41541-022-00592-9","article-title":"ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys","volume":"7","author":"Avanzato","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_87","unstructured":"University of Oxford (2024). A Phase I Safety and Immunogenicity Study of a Nipah Virus Vaccine, ChAdOx1 NipahB, in Healthy Volunteers Aged 18 to 55 in the UK, University of Oxford. Available online: https:\/\/www.isrctn.com\/editorial\/retrieveFile\/41fa12ba-89a8-4eb3-9e39-df72abff2ce9\/43941."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Monath, T.P., Nichols, R., Feldmann, F., Griffin, A., Haddock, E., Callison, J., Meade-White, K., Okumura, A., Lovaglio, J., and Hanley, P.W. (2023). Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1216225"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Monath, T.P., Nichols, R., Tussey, L., Scappaticci, K., Pullano, T.G., Whiteman, M.D., Vasilakis, N., Rossi, S.L., Campos, R.K., and Azar, S.R. (2022). Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010658"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Loomis, R.J., DiPiazza, A.T., Falcone, S., Ruckwardt, T.J., Morabito, K.M., Abiona, O.M., Chang, L.A., Caringal, R.T., Presnyak, V., and Narayanan, E. (2021). Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.772864"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41591-026-04265-1","article-title":"A structure-based mRNA vaccine for Nipah virus in healthy adults: A phase 1 trial","volume":"32","author":"Ploquin","year":"2026","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-021-00284-w","article-title":"A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus","volume":"6","author":"Geisbert","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/S0140-6736(25)01390-X","article-title":"Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: A single-centre, randomised, observer-blind, placebo-controlled, phase 1 study","volume":"406","author":"Frenck","year":"2025","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"146ra107","DOI":"10.1126\/scitranslmed.3004241","article-title":"A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge","volume":"4","author":"Bossart","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1016\/j.vaccine.2011.06.015","article-title":"A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge","volume":"29","author":"Pallister","year":"2011","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Loomis, R.J., Stewart-Jones, G.B.E., Tsybovsky, Y., Caringal, R.T., Morabito, K.M., McLellan, J.S., Chamberlain, A.L., Nugent, S.T., Hutchinson, G.B., and Kueltzo, L.A. (2020). Structure-based design of Nipah virus vaccines: A generalizable approach to paramyxovirus immunogen development. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00842"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.vaccine.2014.02.087","article-title":"Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins","volume":"32","author":"DeBuysscher","year":"2014","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Yoneda, M., Georges-Courbot, M.-C., Ikeda, F., Ishii, M., Nagata, N., Jacquot, F., Raoul, H., Sato, H., and Kai, C. (2013). Recombinant Measles Virus Vaccine Expressing the Nipah Virus Glycoprotein Protects against Lethal Nipah Virus Challenge. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058414"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-017-0023-7","article-title":"A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model","volume":"2","author":"Walpita","year":"2017","journal-title":"npj Vaccines"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41541-024-01036-2","article-title":"Establishing an immune correlate of protection for Nipah virus in nonhuman primates","volume":"9","author":"Promeneur","year":"2024","journal-title":"npj Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/584\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:40:53Z","timestamp":1783532453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":100,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070584"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070584","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}